TORONTO, May 14, 2012 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. (“Transition” or the “Company”) (TSX:TTH) (Nasdaq:TTHI) announced today that a mini-symposium entitled “The Emerging Clinical Profile of Oral Scyllo-inositol (ELND005) in Alzheimer’s Disease: A Dual Mechanism of Action?” was held on Saturday, May 12th, 2012 at the 12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapies. Elan Pharmaceuticals, Inc. has responsibility for the development and commercialization of ELND005. This mini-symposium consisted of the five following presentations:
